At the China International Import Expo, a global pharma giant and a Chinese internet-health platform decided to deepen their relationship. Yicai (First Financial) reported on November 7 that during the 9th CIIE, Novo Nordisk and JD Health held a strategic cooperation upgrade signing ceremony. The two companies already worked together on diabetes, obesity and public health education; now they intend to push further, exploring integrated, patient-centered healthcare services driven by AI.
The upgrade puts AI and big-data technology to work in three scenarios — disease education, patient services and chronic disease management. What that means in practice is intelligent health interaction, personalized disease education, and service-process optimization for efficiency. The ambition here goes beyond an AI that answers health questions. It is meant to connect disease knowledge, professional consultation and long-term management services into one flow.
The two captains were pointing in the same direction. Cao Dong, JD Health CEO and member of JD.com's management committee, said AI is pushing healthcare from single-point digitalization to full-process coordination, with JD Health's digital platform, internet hospital and online-offline scenarios complementing Novo Nordisk's expertise in diabetes and obesity. Dr. Cai Yan, Novo Nordisk senior vice president and president of Greater China, framed it from the other side, saying the company expects to combine its disease-area expertise with JD Health's digital technology to bring scientific knowledge and professional support to more patients.
On paper, the plan splits into an online half and an offline one. The online side leans on JD Health's platform and internet hospital to build disease-education zones, professional content, interactive tools and joint campaigns. Offline, the company's self-operated physical-examination centers, medical-aesthetics and premium health-management facilities will carry risk screening, health education, medication guidance and long-term management into more settings. The point of the pairing is obvious — link online services with offline experience.
Chronic disease management is a long-slope track for medical AI, and for a clear reason. Diabetes and obesity demand long-term follow-up, medication education and continuous data monitoring, which is exactly where conversational AI and connected data create the most value. The pharma-platform bond is shifting, too, from a drug-sales channel toward a service community. The signing itself is only a starting point. Whether AI truly shortens the path from diagnosis to standardized management will be judged by the quality of delivery in the scenes to come.